La Jolla Pharmaceutical (NASDAQ:LJPC) has been assigned an average recommendation of “Hold” from the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.50.
A number of equities research analysts have recently weighed in on LJPC shares. ValuEngine upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Friday. HC Wainwright downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 26th. SunTrust Banks downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. Finally, BidaskClub downgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, September 27th.
Shares of LJPC remained flat at $$3.89 during mid-day trading on Tuesday. 347,801 shares of the stock were exchanged, compared to its average volume of 981,053. The business’s fifty day moving average price is $3.95 and its 200 day moving average price is $7.70. La Jolla Pharmaceutical has a one year low of $2.30 and a one year high of $13.90. The company has a market cap of $105.64 million, a P/E ratio of -0.50 and a beta of 2.05.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative net margin of 683.88% and a negative return on equity of 715.11%. The company had revenue of $5.71 million during the quarter, compared to analyst estimates of $6.96 million. As a group, equities analysts anticipate that La Jolla Pharmaceutical will post -4.43 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of LJPC. Sio Capital Management LLC bought a new position in La Jolla Pharmaceutical in the 2nd quarter valued at approximately $12,121,000. Boxer Capital LLC bought a new position in La Jolla Pharmaceutical in the 2nd quarter valued at approximately $5,319,000. SG Americas Securities LLC raised its holdings in La Jolla Pharmaceutical by 394.8% in the 3rd quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock valued at $3,309,000 after buying an additional 299,995 shares during the last quarter. VHCP Management III LLC raised its holdings in La Jolla Pharmaceutical by 24.7% in the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock valued at $11,580,000 after buying an additional 248,298 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its holdings in La Jolla Pharmaceutical by 53.3% in the 2nd quarter. Rock Springs Capital Management LP now owns 425,000 shares of the biopharmaceutical company’s stock valued at $3,931,000 after buying an additional 147,764 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Read More: Which market index is the best?
Receive News & Ratings for La Jolla Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.